

Correlation Between *hlyA* and *cnf1* Virulent Genes with Antibiotic Resistance and non-ESBLs *Escherichia coli* Isolates Collected from Patient with Urinary Tract Infections in Kerman, Iran

Zahra Hashemizadeh,¹ Davood Kalantar-Neyestanaki,^{1,2} and Shahla Mansouri^{1,3,*}

¹Department of Microbiology and Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

²Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

³Research Center for Infectious Diseases and Tropical Medicine, Kerman, Iran

*Corresponding author: Dr. Shahla Mansouri, Department of Microbiology and Virology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Tel/Fax: +98-3433257665, E-mail: smansouri@kmu.ac.ir

Received 2016 July 06; Revised 2016 October 04; Accepted 2016 October 28.

Abstract

Background: *Escherichia coli* is the most common cause of urinary tract infections. Different studies have been reported that acquisition of drug resistance mechanism may be related to loss of virulent factors. In this study, we investigated the correlation of antibiotic resistance and ESBLs production with presence of *hlyA* and *cnf1* virulence genes.

Methods: During June 2014 to March 2015, 250 *Escherichia coli* isolates were collected from different patients with urinary tract infections in Kerman, Iran. Disk diffusion method was used for determination of antibiotic susceptibility profile and combined disk method was used for detection of ESBLs producing isolates. The *hlyA* and *cnf1* genes were detected by PCR method.

Results: In total, 44.8% of isolates were considered as extended spectrum beta-lactamases (ESBLs) producing by combined disk method. *hlyA* and *cnf1* genes were detected in 28.8% and 29.2% of isolates, respectively. Statistical analysis revealed significant correlations between susceptibility to NA, CIP, CTX, CAZ, PIT antibiotics with *hlyA* and *cnf1* positive isolates and also significant correlation observed between ESBLs negative isolates with *hlyA* positive isolates (P value < 0.05).

Conclusions: Acquire of antibiotic resistance mechanism may lead to loss of virulence factor.

Keywords: Antibiotic Resistance, ESBLs, Virulence Genes, *Escherichia coli*

1. Background

Escherichia coli is a gram-negative bacilli, which is able to colonize in humans (1). This bacterium is the most common cause of urinary tract infections (UTIs) in all age groups (2). Ability of *E. coli* in the pathogenesis is dependent on the virulent factors (2, 3). Several virulent factors including hemolysin (*hlyA*) and cytotoxic necrotizing factor type 1 (*cnf1*) are responsible for pathogenic potential of uropathogenic *E. coli* isolates (UPEC) (3, 4). These virulence factors are involved in damage to the tissues as well as bacterial dissemination (3, 4). Antibiotic resistance is another important factor in ability of *E. coli* in the pathogenesis and increased of morbidity and mortality of patients (5). At the moment, multi-drug resistant (MDR) and ESBLs producing isolates of *E. coli* have been reported worldwide and treatment options for MDR isolates is limited (5, 6). Several studies have been reported that acquisition of drug resistance mechanism may be related to loss of virulent factors (4, 6). Therefore, the aim of this study was determinate of correlation between antibiotic resistance and ESBLs production with presence of virulent genes *hlyA* and *cnf1* in *E. coli* iso-

lates collected from patients with a UTI in Kerman, Iran.

2. Methods

2.1. Sample Collection and Identification of Isolates

In a cross-sectional study, we collected 250 non-duplicate isolates of *E. coli* during June 2014 to March 2015 from patients with symptoms of a urinary tract infection who were admitted to the university-affiliated hospital in Kerman. Basic characteristics data such as gender and age were recorded. Bacterial isolates were identified by standard and biochemical methods including: oxidase test, lactose fermentation, growth on Triple Sugar Iron (TSI), Simmons' Citrate Agar Media, and MRVP test (7) (All the culture media were from Merck, Co, Germany.).

2.2. Antibiotics Susceptibility of Isolates

The disk diffusion method was used for determination of antimicrobial susceptibility profile of isolates according to the Clinical and Laboratory Standard (CLSI) (8). The following antibiotics (Mast, UK) were tested: imipenem (IMI:10 µg), ceftazidime (CAZ: 30 µg), cefotaxime (CTX:

30 µg), amoxicillin/clavulanic acid (AUG: 20/10 µg), cefepime (CPM: 30 µg), Piperacillin/tazobactam (PIZ: 100/10 µg), nalidixic acid (NA: 30 µg), and ciprofloxacin (CIP: 5 µg). *E. coli* ATCC 25922 was used as control strain in antimicrobial susceptibility test (8).

2.3. Detection of ESBLs Producing Isolates

ESBLs producing isolates was detected by combined disk method with clavulanic acid according to CLSI guideline (8). The following antibiotics (Mast, UK) were used for ESBLs detection: CAZ (30 µg), CTX (30 µg), CPD (30 µg) alone as well as with 10 µg clavulanic acid. *Klebsiella pneumonia* ATCC 700603 (ESBLs positive) and *E. coli* ATCC 25922 (ESBLs negative) were used as control strains (8).

2.4. Detection of *hlyA* and *cnf1* Virulent Genes

The total DNA was extracted by the boiling method (9). Virulent genes included *hlyA* and *cnf1* detected by polymerase chain reaction (PCR). Specific oligonucleotide were: *hlyA*-F- 5'-AAC AAG GAT AAG CAC TGT TCT GGCT-3' and *hlyA*-R- 5'-ACC ATA TAA GCG GTC ATT CCC GTCA for *hlyA*-R gene (Product size: 1177 bp) (10) and *cnf1*-F- 5'-AAG ATG GAG TTT CCT ATG CAG GAG-3' and *cnf1*-R- 5'-CAT TCA GAG TCCT GGC CCT CAT TAT T for *cnf1* gene (Product size: 543 bp) (11). The PCR amplification was carried out in Biometra PCR Thermal Cycler by using PCR Master mix (Ampliqon Inc, Denmark) according to manufacture guideline, under the following conditions: initial denaturation for 5 minutes at 95°C followed by 30 cycles of 60 seconds at 95°C, and 45 seconds annealing at the specific melting temperature of each primer (62°C for *hlyA* and 62°C for *cnf1*). PCR assay was performed in a total volume of 15 µL containing: 0.5 µL of each primer (10 pM), 7.5 µL of PCR Master mix, 1 µL of DNA (20 ng) and 5.5 µL of H₂O (DNase and RNase free water). PCR products were electrophoresis in 1% agarose gel.

2.5. Statistical Analysis

SPSS v.22 (SPSS Inc., Chicago, IL, USA) was used for data analysis. We used the Chi-squared test to assess the variables correlation between antibiotic resistance and ESBLs producing with presence of *hlyA* and *cnf1* genes. P value < 0.05 was considered statistically significant.

3. Results

The age of the patients with a UTI ranged from 1 - 93 years. Among 250 UPEC isolates, 193 (77.2%) isolates were from females and 57 (22.8%) were from males. The rate of resistance to imipenem (IMI:10 µg), cef-tazidime (CAZ: 30 µg), cefotaxime (CTX: 30 µg), amoxi-cillin/clavulanic acid (AUG: 20/10 µg), cefepime (CPM: 30

µg) and piperacillin/tazobactam (PIZ: 100/10 µg), nalidixic acid (NA: 30 µg) as well as ciprofloxacin (CIP: 5 µg) antibiotics were 4.8%, 46%, 47.2%, 61.6%, 46.8%, 24%, 68%, and 55.2%, respectively. In total, 44.8% of isolates were ESBLs positive. *hlyA* and *cnf1* genes detected in 28.8% and 29.2% of isolates, respectively (Figure 1). Co-exist of *hlyA* and *cnf1* genes observed in 23.2% of isolates. *hlyA* and *cnf1* genes observed in 8% and 10% among of ESBLs positive isolates, respectively. Prevalence of NA, CIP, CTX, CAZ, PIT-sensitive isolates were over NA, CIP, CTX, CAZ, PIT-resistant isolates among the UPEC isolates with the *cnf1* and *hlyA* (Table 1). Statistical analysis revealed significant correlation between susceptibility to NA, CIP, CTX, CAZ, PIT antibiotics with presence of *hlyA* and *cnf1* in isolates and also significant correlation observed between ESBLs negative (non ESBLs) isolates with *hlyA* positive isolates (P value < 0.05) (Table 1). In our study, there was no significant correlation with age and gender of patients with presence of *hlyA* and *cnf1* in isolates.

Figure 1. Agarose Gel Electrophoresis of PCR Amplified *hlyA* and *cnf1* Genes



N; Negative Control, P; Positive Control, 1 and 2; Positive Isolates for *hlyA* gene, 3; Positive Isolates for *cnf1* Gene, M; DNA Size Marker.

4. Discussion

Virulence factors such as *hlyA* and *cnf1* in UPEC isolates are involved in pathogenicity of this bacterium (2, 4, 6).

Table 1. Distribution of Antibiotic Susceptibility and ESBLs Producing with *hlyA* and *cnfI* Genes Positive Isolates

Virulent Genes (n)	Antibiotic Agents and Rate of Resistance to Deferent Antibiotic, No. (%)								
	NA	CIP	CTX	CAZ	CPM	IMI	PIZ	AUG	ESBLs
	R, 170 (68)	R, 138 (55.2)	R, 118 (47.2)	R, 115 (46)	R, 117 (46.8)	R, 12 (4.8)	R, 60 (24)	R, 154 (61.6)	P, 112 (44.8) N, 138 (55.2)
<i>hlyA</i> (72)	28 (16.4)	25 (18.1)	24 (20.3)	22 (14.1)	28 (23.9)	5 (41.6)	11 (18.3)	27 (17.5)	20 (17.8) 52 (37.6)
<i>cnfI</i> (73)	35 (20.5)	28 (20.2)	27 (22.8)	25 (21.7)	29 (24.7)	5 (41.6)	11 (18.3)	28 (18.1)	25 (22.3) 48 (34.7)

Abbreviations: AUG, Amoxicillin/Clavulanic; CAZ, Ceftazidime; CIP, Ciprofloxacin; CPM, Cefepime; CTX, Cefotaxime; IMI, Imipenem; N, Negative; NA, Nalidixic Acid; P, Positive; PIZ, Piperacillin/Tazobactam; R, Resistant.

The prevalence hemolysin (*hlyA* gene) and cytotoxic necrotizing factor type 1 (*cnfI* gene) among UPEC isolates were 28.8% and 29.2%, respectively. The prevalence of *hlyA* and *cnfI* in our study were similar to other studies in Iran. The prevalence of the *hlyA* gene was 23.3% in UPEC isolated from Iranian patient with UTI, in Jahrom Iran (12). In another study in Iran, prevalence of *hlyA* and *cnfI* genes has been reported as 13.5% and 22.9%, respectively (13).

In agreement to other studies, prevalence of resistance to NA, CIP, CTX, CAZ, CPM, and AUG is high in our city. The rate of resistance to NA, CIP, CTX, CAZ, and AUG were reported about 53%, 51%, 69%, 72%, 77%, respectively, in Tehran, Iran (14). Furthermore, the rate of ESBLs producing isolates in our study in similar to other studies in Iran (14). In several studies in Iran, ESBLs isolates were reported in 20% to 89.8% in different regions in Iran (14, 15).

Correlations between virulent genes with antibiotic resistance in UPEC isolates have been investigated in many studies in different country of worldwide (4, 6, 16). In the present study, we observed a statistically significance between antimicrobial susceptibilities and presence of *hlyA* and *cnfI* genes ($P < 0.05$).

In our study, we observed that the *hlyA* and *cnfI* positive isolates were significantly associated with the sensitivity to NA, CIP, CTX, CAZ, and PIT as well as with the non-ESBL isolates. Harwalkar et al. reported that prevalence of *hlyA* and *cnfI* in CIP-sensitive isolates is higher than in ciprofloxacin-resistant of UPEC isolates (4). Unlike Harwalkar et al., we observed an increased prevalence of the *cnfI* gene in the non-ESBL isolates compared to the ESBL positive isolates; however, the difference was not statistically significant and the *hlyA* gene showed a significant association with the ESBL negative isolates (4).

Also, our study, similar to Velasco et al., showed that the resistance to nalidixic acid caused loss of virulence genes; therefore, resistance to nalidixic acid may lead to the loss of the ability to pathogenicity (17). In a study done by Arisoy et al., they showed an association between susceptibility to antibiotics and virulence factors in the *E. coli* isolates recovered from UTI patients (18). Similar to the present study, they reported that virulence gene *hlyA* was increased in sensitive isolates. Furthermore, Asadi et al. showed

stronger associations between virulence factors and antibiotic resistance in UPEC isolates (12).

Finally, our findings in agreement with other studies suggested that resistance to NA, CIP, and ESBLs production may be associated with marked reduction in pathogenicity of UPEC isolates (4, 6, 17).

4.1. Conclusion

The study showed that, there are a many statistically significances between non-resistance and non-ESBLs with presence of *hlyA* and *cnfI* genes. Our findings, similar to other studies, show that acquire of antibiotic resistance mechanism may be lead to loss of virulence factor.

Footnotes

Conflicts to Interests: None declared.

Funding/Support: This research has been supported by Kerman University of Medical Sciences and Health Services grant no 94/497.

References

- Birosova E, Siegfried L, Kmet'ova M, Makara A, Ostro A, Gresova A, et al. Detection of virulence factors in alpha-haemolytic *Escherichia coli* strains isolated from various clinical materials. *Clin Microbiol Infect*. 2004;10(6):569-73. doi: [10.1111/j.1469-0691.2004.00922.x](https://doi.org/10.1111/j.1469-0691.2004.00922.x). [PubMed: 15191387].
- Navidinia M, Najar Peerayeh S, Fallah F, Bakhshi B. Phylogenetic groups and pathogenicity island markers in *Escherichia coli* isolated from children. *Jundishapur J Microbiol*. 2013;6(10) doi: [10.5812/jjm.8362](https://doi.org/10.5812/jjm.8362).
- Sobieszczanska BM, Osek J, Gryko R, Dobrowolska M. Association between cell-bound haemolysin and cell-detaching activity of *Escherichia coli* isolated from children. *J Med Microbiol*. 2006;55(Pt 3):325-30. doi: [10.1099/jmm.0.46111-0](https://doi.org/10.1099/jmm.0.46111-0). [PubMed: 16476797].
- Harwalkar A, Gupta S, Rao A, Srinivasa H. Lower prevalence of *hlyD*, *papC* and *cnfI* genes in ciprofloxacin-resistant uropathogenic *Escherichia coli* than their susceptible counterparts isolated from southern India. *J Infect Public Health*. 2014;7(5):413-9. doi: [10.1016/j.jiph.2014.04.002](https://doi.org/10.1016/j.jiph.2014.04.002). [PubMed: 24861644].
- Soltani J, Poorabbas B, Miri N, Mardaneh J. Health care associated infections, antibiotic resistance and clinical outcome: A surveillance study from Sanandaj, Iran. *World J Clin Cases*. 2016;4(3):63-70. doi: [10.12998/wjcc.v4.i3.63](https://doi.org/10.12998/wjcc.v4.i3.63). [PubMed: 26989670].

6. Tabasi M, Asadi Karam MR, Habibi M, Yekaninejad MS, Bouzari S. Phenotypic Assays to Determine Virulence Factors of Uropathogenic *Escherichia coli* (UPEC) Isolates and their Correlation with Antibiotic Resistance Pattern. *Osong Public Health Res Perspect*. 2015;**6**(4):261-8. doi: [10.1016/j.phrp.2015.08.002](https://doi.org/10.1016/j.phrp.2015.08.002). [PubMed: [26473094](https://pubmed.ncbi.nlm.nih.gov/26473094/)].
7. Martin WJ, Washington II JA. In: Manual of clinical microbiology. 3rd ed. Lennette EH, Balows A, Hausler Jr WJ, Truant JP, editors. Washington. D.C.: American Society for Microbiology; 1980. pp. 195-219. Enterobacteriaceae.
8. Clinical and Laboratory Standards Institute . Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. M100-S24. 2015 ;**34**(1):44-50.
9. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. Detection of *Pseudomonas aeruginosa* producing metallo-beta-lactamases in a large centralized laboratory. *J Clin Microbiol*. 2005;**43**(7):3129-35. doi: [10.1128/JCM.43.7.3129-3135.2005](https://doi.org/10.1128/JCM.43.7.3129-3135.2005). [PubMed: [16000424](https://pubmed.ncbi.nlm.nih.gov/16000424/)].
10. Blanco M, Blanco JE, Rodríguez E, Abalía I, Alonso MP, Blanco J. Detection of virulence genes in uropathogenic *Escherichia coli* by polymerase chain reaction (PCR): comparison with results obtained using phenotypic methods. *J Microbiol Methods*. 1997;**31**(1-2):37-43. doi: [10.1016/S0167-7012\(97\)00087-0](https://doi.org/10.1016/S0167-7012(97)00087-0).
11. Yamamoto S, Terai A, Yuri K, Kurazono H, Takeda Y, Yoshida O. Detection of urovirulence factors in *Escherichia coli* by multiplex polymerase chain reaction. *FEMS Immunol Med Microbiol*. 1995;**12**(2):85-90. doi: [10.1111/j.1574-695X.1995.tb00179.x](https://doi.org/10.1111/j.1574-695X.1995.tb00179.x). [PubMed: [8589667](https://pubmed.ncbi.nlm.nih.gov/8589667/)].
12. Asadi S, Kargar M, Solhjoo K, Najafi A, Ghorbani-Dalini S. The association of virulence determinants of uropathogenic *Escherichia coli* with antibiotic resistance. *Jundishapur J Microbiol*. 2014;**7**(5) doi: [10.5812/jjm.9936](https://doi.org/10.5812/jjm.9936).
13. Farshad S, Emamghorashi F. The prevalence of virulence genes of *E. coli* strains isolated from children with urinary tract infection. *Saudi J Kidney Dis Transpl*. 2009;**20**(4):613-7. [PubMed: [19587502](https://pubmed.ncbi.nlm.nih.gov/19587502/)].
14. Abdi S, Ranjbar R, Hakemi Vala M, Jonaidi N, Bagheri Bejestany O, Bagheri Bejestany F. Frequency of bla TEM, bla SHV, bla CTX-M, and qnrA among *Escherichia coli* isolated from urinary tract infection. *Arch Clin Infect Dis*. 2014;**9**(1) doi: [10.5812/archcid.18690](https://doi.org/10.5812/archcid.18690).
15. Riyahi Zaniani F, Meshkat Z, Naderi Nasab M, Khaje-Karamadini M, Ghazvini K, Rezaee A. The Prevalence of TEM and SHV Genes among Extended-Spectrum Beta-Lactamases Producing *Escherichia coli* and *Klebsiella pneumoniae*. *Iran J Basic Med Sci*. 2012;**15**(1):654-60.
16. Staji H, Khoshgoftar J, Javaheri Vayeghan A, Salimi Bejestani MR. Phylogenetic grouping and assessment of virulence genotypes, with antibiotic resistance patterns, of *Escherichia coli* strains implicated in female urinary tract infections. *Int J Enteric Pathog*. 2016;**4**(1) doi: [10.17795/ijep31609](https://doi.org/10.17795/ijep31609).
17. Velasco M, Horcajada JP, Mensa J, Moreno-Martinez A, Vila J, Martinez JA, et al. Decreased invasive capacity of quinolone-resistant *Escherichia coli* in patients with urinary tract infections. *Clin Infect Dis*. 2001;**33**(10):1682-6. doi: [10.1086/323810](https://doi.org/10.1086/323810). [PubMed: [11595990](https://pubmed.ncbi.nlm.nih.gov/11595990/)].
18. Arisoy M, Rad AY, Akin A, Akar N. Relationship between susceptibility to antimicrobials and virulence factors in paediatric *Escherichia coli* isolates. *Int J Antimicrob Agents*. 2008;**31** Suppl 1:S4-8. doi: [10.1016/j.ijantimicag.2007.07.030](https://doi.org/10.1016/j.ijantimicag.2007.07.030). [PubMed: [17959360](https://pubmed.ncbi.nlm.nih.gov/17959360/)].